"Aza Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic chemicals where carbon atoms have been replaced by nitrogen atoms.
| Descriptor ID |
D001372
|
| MeSH Number(s) |
D02.145
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Aza Compounds".
Below are MeSH descriptors whose meaning is more specific than "Aza Compounds".
This graph shows the total number of publications written about "Aza Compounds" by people in this website by year, and whether "Aza Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 2 | 1 | 3 |
| 2006 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aza Compounds" by people in Profiles.
-
The effect of treatment with moxifloxacin or azithromycin on acute bacterial rhinosinusitis in mice. Int J Infect Dis. 2006 Sep; 10(5):401-6.
-
Vitreous and aqueous penetration of orally administered moxifloxacin in humans. Arch Ophthalmol. 2006 Feb; 124(2):178-82.
-
Determination of aqueous and vitreous concentration of moxifloxacin 0.5% after delivery via a dissolvable corneal collagen shield device. J Cataract Refract Surg. 2005 Nov; 31(11):2142-6.
-
Nocardia keratitis after laser in situ keratomileusis: clinicopathologic correlation. J Cataract Refract Surg. 2005 Oct; 31(10):2012-5.
-
Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Arch Ophthalmol. 2005 Jan; 123(1):39-44.
-
Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration. Trans Am Ophthalmol Soc. 2004; 102:149-55; discussion 155-7.
-
Discovery of an orally efficacious inhibitor of coagulation factor Xa which incorporates a neutral P1 ligand. J Med Chem. 2003 Feb 27; 46(5):681-4.
-
Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J Antimicrob Chemother. 2000 May; 45(5):583-90.
-
A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux. Antimicrob Agents Chemother. 2000 Mar; 44(3):798-801.